Literature DB >> 9269992

Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity.

P F Muhlradt1, F Sasse.   

Abstract

Epothilones are a new class of potential antitumor compounds that were isolated from the myxobacterium Sorangium cellulosum. Epothilones have effects on the cytoskeleton similar to those of the antineoplastic drug Taxol. Both compounds inhibit cell proliferation by stabilizing microtubuli, and they compete for the same binding site. In addition, Taxol displays endotoxin-like properties in that it activates macrophages to synthesize proinflammatory cytokines and nitric oxide. We measured nitric oxide release by IFN-gamma-treated murine macrophages as an indicator of macrophage activation by epothilone B. Although epothilone B showed the expected effects on the microtubuli, there was no indication of macrophage stimulatory activity by epothilone B, nor did epothilone B inhibit lipopolysaccharide-mediated nitric oxide release. We conclude that, unlike Taxol, epothilone-mediated microtubuli stabilization does not trigger endotoxin-signaling pathways. Moreover, because the endotoxin-like activity of Taxol may be the cause of some nonhematological clinical side effects, it is to be expected that such effects may not occur with epothilones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269992

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton.

Authors:  A Dietzmann; D Kanakis; E Kirches; S Kropf; C Mawrin; K Dietzmann
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

3.  A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Authors:  David M Peereboom; Jeffrey G Supko; Kathryn A Carson; Tracy Batchelor; Surasak Phuphanich; Glenn Lesser; Tom Mikkelsen; Tom Mikkelson; Joy Fisher; Serena Desideri; Xiaoying He; Stuart A Grossman
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

4.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

Authors:  T C Chou; X G Zhang; C R Harris; S D Kuduk; A Balog; K A Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  The antibody catalysis route to the total synthesis of epothilones.

Authors:  S C Sinha; C F Barbas; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

Authors:  M M Moasser; L Sepp-Lorenzino; N E Kohl; A Oliff; A Balog; D S Su; S J Danishefsky; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 7.  Epothilones: From discovery to clinical trials.

Authors:  Stefano Forli
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

8.  A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.

Authors:  Jin Zhang; Jing Zhou; Xiaomei Ren; Yanyan Diao; Honglin Li; Hualiang Jiang; Ke Ding; Duanqing Pei
Journal:  Invest New Drugs       Date:  2010-11-16       Impact factor: 3.850

9.  Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

Authors:  T C Chou; X G Zhang; A Balog; D S Su; D Meng; K Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Authors:  T Natsume; J Watanabe; S Tamaoki; N Fujio; K Miyasaka; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2000-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.